MedTrace Logo

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

NCT02626338 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-12-20

Study results available
· View outcomes & findings →

Summary

The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interventions

DRUG

Crenolanib

DRUG

Mitoxantrone

DRUG

Cytarabine

DRUG

Etoposide

DRUG

Fludarabine

DRUG

G-CSF

DRUG

Idarubicin

Sponsors & Collaborators

  • Arog Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626338 on ClinicalTrials.gov